Tfg Asset Management Gp LTD Freeline Therapeutics Holdings PLC Transaction History

Tfg Asset Management Gp LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.69 - $1.1 $165,249 - $263,441	239,492 Added 6.37%	4,000,000 $2.8 Million
Q2 2022 Aug 15, 2022	BUY	$0.69 - $1.12 $41,750 - $67,768	60,508 Added 1.64%	3,760,508 $3.27 Million
Q1 2022 May 16, 2022	BUY	$0.92 - $2.03 $2 Million - $4.42 Million	2,177,141 Added 142.96%	3,700,000 $4.14 Million
Q4 2021 Feb 14, 2022	BUY	$1.97 - $3.45 $833,032 - $1.46 Million	422,859 Added 38.44%	1,522,859 $3.02 Million
Q3 2021 Nov 15, 2021	BUY	$3.04 - $8.9 $1.06 Million - $3.12 Million	350,000 Added 46.67%	1,100,000 $3.75 Million
Q4 2020 Feb 12, 2021	BUY	$14.94 - $18.3 $298,800 - $366,000	20,000 Added 2.74%	750,000 $13.7 Million
Q3 2020 Nov 13, 2020	BUY	$15.45 - $18.12 $11.3 Million - $13.2 Million	730,000 New	730,000 $11.4 Million

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Tfg Asset Management Gp LTD, based on Form 13F filings with the SEC.

Stay updated on Tfg Asset Management Gp LTD with notifications on news.